GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tevogen Bio Holdings Inc (FRA:G28) » Definitions » Cash Flow from Others

Tevogen Bio Holdings (FRA:G28) Cash Flow from Others : €-36.26 Mil (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Tevogen Bio Holdings Cash Flow from Others?

Tevogen Bio Holdings's cash flow from others for the three months ended in Dec. 2024 was €0.08 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Dec. 2024 was €-36.26 Mil.


Tevogen Bio Holdings Cash Flow from Others Historical Data

The historical data trend for Tevogen Bio Holdings's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tevogen Bio Holdings Cash Flow from Others Chart

Tevogen Bio Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Cash Flow from Others
9.72 -9.60 47.12 -37.66

Tevogen Bio Holdings Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash Flow from Others Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.49 -37.15 1.10 -0.29 0.08

Tevogen Bio Holdings Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-36.26 Mil.

Tevogen Bio Holdings Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of Tevogen Bio Holdings's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.


Tevogen Bio Holdings Business Description

Traded in Other Exchanges
Address
15 Independence Boulevard, Warren, NJ, USA, 07059
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

Tevogen Bio Holdings Headlines

No Headlines